Present status of the detection of antifungal resistance: The perspective from both sides of the ocean

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 2, 2001, Pages 46-53

  Roilides, E ^a   Farmaki, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE;

AGAR GEL DIFFUSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CONTROLLED STUDY; CORRELATION FUNCTION; CULTURE MEDIUM; FUNGUS CULTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INOCULATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; YEAST;

ANIMALIA; FUNGI;

EID: 0035747107     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00074.x     Document Type: Article

References (65)

1. Antifungal agents and antifungal susceptibility testing
2. Antifungal agents and susceptibility tests
3. Antifungal susceptibility testing
4. Clinical utility of in vitro antifungal susceptibility testing
5. Susceptibility testing of fluconazole: Evaluation of a multicenter study of the working group 'Clinical Mycology' of the German Speaking Mycological Society
6. Grupo de trabajo para el estudio de fungemias. Estudio multicéntrico sobre fungemias por levaduras en España (abril-junio 1997)
7. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended macrodilution testing of amphotericin B, fluconazole and flucytosine
8. Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in-vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
9. Collaborative comparison of broth macro-and microdilution antifungal tests
10. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for tests automation
11. Influence of incubation time, inoculum size, and glucose concentration on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole
12. Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility
13. Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans
14. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method
15. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to tests five antifungal agents, including the new triazole D0870
16. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and Candida albicans
17. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
18. Improved médium for fluconazole susceptibility testing of Candida albicans
19. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standard's proposed standard
20. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing flucytosine, and fluconazole against Candida albicans
21. The trailing end point phenotype in antifungal susceptibility testing is pH dependent
22. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
23. Effect of media on growth rate and susceptibility testing of C. neoformans
24. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: A comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose
25. Fluconazole susceptibility testing of C. neoformans: Comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients
26. Oxygen is a limiting nutrient for growth of C. neoformans
27. Detection of amphotericin B-resistant Candida isolates in a broth-based system
28. Detection to resistance to amphotericin B among C. neoformans clinical isolates: Performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies
29. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
30. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
31. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animals infection models
32. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
33. Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods
34. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi
35. Iso-sensitest broth: A semi-defined medium with enhanced ability to detect amphotericin b (amb) resistant Candida isolates
36. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole
37. Defining conditions for microbroth antifungal susceptibility testing: Influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria
38. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
39. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods
40. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
41. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
42. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
43. Comparative in-vitro activity of voriconazole (UK109-496) and other six antinfungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
44. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeasts isolates
45. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Cryptococcus spp. & other yeasts and yeast-like organisms
46. Fluconazole disk diffusion procedure for determining susceptibility of Candida species
47. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group
48. Disk diffusion susceptibility testing of dermatophytes with imidazoles
49. An interlaboratory evaluation of the E test method for antifungal susceptibility testing of pathogenic yeasts for five antifungal agents using Casitone agar and solidified RPMI 1640 with 2% glucose
50. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds
51. Determination of antifungal MICs by a rapid susceptibility assay
52. Estimation of minimum sterol 14alpha-demethylation-inhibitory concentration of azoles in Candida yeasts using acetate-mediated growth inhibition: Potential utility in susceptibility testing
53. Quantitation of Candida albicans ergosterol content improves the correlation between In vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis
54. Evaluation of five commercial antifungal susceptibility testing systems
55. Comparative evaluation of PASCO and National Committee for Clinical Laboratory Standards M27-A broth microdilution methods for antifungal susceptibility testing of yeasts
56. Correlation between in vitro susceptibility determined by Etest and response to therapy with amphotericin B. Results from a multicenter prospective study of candidemia
57. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection
58. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
59. Itraconazole resistance in Aspergillus fumigatus
60. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
61. Correlation between in vitro and in vivo activity of antifungal agents against Candida species
62. Clinical cellular, and molecular factors that contribute to antifungal drug resistance